/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Significant Progress in Timber Pharmaceuticals' Phase 3 ASCEND Study Timber Pharmaceuticals (NYSE American: TMBR), a clinical-stage biopharmaceutical company specializing in
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 1.33% and 8.53%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
Curis (CRIS) delivered earnings and revenue surprises of -9.09% and 7.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Timber Pharmaceuticals, Inc. (TMBR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement...
Timber Pharmaceuticals, Inc. (NYSE American: TMBR) is engaged as a clinical-stage biopharmaceutical company, which is focused on the development and
AVEO (AVEO) delivered earnings and revenue surprises of 11.11% and 2.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Basking Ridge, NJ, Aug. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR),...
Pivotal Trial Expected to Enroll More Than 140 Patients With Moderate to Severe Congenital Ichthyosis at Leading Research Centers in the U.S., Canada,...
- Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial - BASKING RIDGE, NJ, May 31, 2022 (GLOBE NEWSWIRE) -- via...